CTOs on the Move

Frontier Medicines

www.frontiermeds.com

 
Frontier Medicines is a pre-clinical stage biopharmaceutical company developing breakthrough medicines that redefine the course of debilitating diseases. According to the American Cancer Society, 1,762,000 new cancer cases and 607,000 deaths from cancer are expected to occur in the US in 2019. Our focus is developing treatments against important cancer-causing proteins that the biopharma industry hasn`t found a way to treat (or “drug”) with pharmaceutical interventions. After decades of research, this has become one of the most critical challenges in addressing human disease and advancing oncology therapy --central to the research at Frontier Medicines. Frontier Medicines is using chemoproteomics – ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.frontiermeds.com
  • 151 Oyster Point Boulevard 2nd Floor
    South San Francisco, CA USA 94080
  • Phone: 650.457.1005

Executives

Name Title Contact Details
James Winkler
Head of Degrader Technology Profile
Johannes Hermann
Chief Technology Officer Profile

Funding

Frontier Medicines raised $M67 on 06/25/2019

Similar Companies

Curie Co

Curie Co is replacing chemicals with clean, sustainable proteins and enzymes.

Exonics Therapeutics

Exonics Therapeutics was launched in February 2017 to advance the research of our scientific founder, Dr. Eric Olson and his laboratory at the University of Texas Southwestern Medical Center (UTSW) to develop treatments for patients with neuromuscular diseases. Dr. Olson is one of the world’s leading experts in the study of muscle cells and the application of gene editing to treat these types of diseases. In particular, Dr. Olson’s laboratory has used adeno-associated virus (AAV) to deliver a CRISPR/Cas9 technology that can identify and repair exon mutations to restore the production of dystrophin, a protein that helps stabilize and protect muscle fibers. Dystrophin is the protein missing in boys with Duchenne. The loss of dystrophin causes Duchenne.

BioSkryb

Bioskryb is a venture-backed startup bringing new solutions for cellular heterogeneity, in both the research and clinical space studies, using a proprietary genome amplification system.